Report

  1. Home
  2. Discounted reports

Veterinary Vaccine Adjuvants Market By Type (Alum and Calcium Salts, Oil Emulsion Adjuvants, Liposomes and Archaeosomes, Nanoparticles and Microparticles, Others) , By Route of Administration (Oral, Subcutaneous, Intramuscular, Others) By Type of Animal (Livestock Animals, Companion Animals) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Market Report I 2024-07-01 I 280 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

Veterinary Vaccine Adjuvants Market
The veterinary vaccine adjuvants market was valued at $0.4 billion in 2023 and is projected to reach $0.6 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.
A veterinary vaccine adjuvant is an element essential to enhance the immune response of the administered vaccine in animals. An adjuvant is a bioactive compound that upon addition elevates the immune response generated by vaccines. The mechanism of action of adjuvants involves enhancement in the antigen presentation process or modulation of immune pathways through the stimulation of certain receptors. The most common forms of adjuvants included in veterinary vaccines are oil emulsions, aluminum salts,liposomes, bacterial derivatives, and saponins.
Increase in the trend of petkeeping and surge in expenditure on their health are the key drivers of the veterinary vaccine adjuvants market. Moreover, the prevalence of diseases in animals has upsurged over the past few years, thereby boosting the demand for veterinary vaccine adjuvants. In recent times, the addition of nanoparticle-based adjuvants in vaccines is trending in the market as they offer controlled release and encapsulate the antigens, thus preventing their degradation. Furthermore, microparticle-based and genetic adjuvants are acquiring prominent traction owing to their highly targeted action mechanism.
However, several adjuvants potentially cause severe systemic reactions and local reactogenicity in animals, raising concerns pertaining to their safety and hampering the development of the market. In addition, advancements in vaccine development are eliminating the requirement of adjuvants, without limiting the efficacy of vaccines. Such innovations are anticipated to restrain the development of the market in upcoming years. Despite the innovations in vaccine formation, several gaps exist in the generation of effective immune response, such as pathogen variability and virulent reversion of vaccine strains. These shortcomings present lucrative opportunities for the players in the veterinary vaccineadjuvant market. Further, the implementation of different veterinary vaccination drives by governments, such as the foot and mouth disease vaccination program by the Department of Animal Husbandry & Dairying in India, open new avenues for market expansion.
Segment Review
The veterinary vaccine adjuvants market is segmented into type, route of administration, type of animal, and region. On the basis of type, the market is divided into alum & calcium salts, oil emulsion adjuvants, liposomes & archaeosomes, nanoparticles & microparticles, and others. By route of administration, it is classified into oral, subcutaneous, intramuscular, and others. As per type of animal, it is bifurcated into livestock animals and companion animals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the alum & calcium salts segment dominated the market in 2023.
By route of administration, the intramuscular segment accounted for a high market share in 2023.
As per type of animal, the livestock animals segment was the highest shareholder in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The leading players operating in theglobal veterinary vaccine adjuvants market include SEPPIC, SPI Pharma, Inc., Bioveta AS, Croda Internation PLC, Merck & Co., Inc., MVP Laboratories, OZ Biosciences, InvivoGen Corporation., Evonik Industries AG, and Zoetis, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Type
- Alum and Calcium Salts
- Oil Emulsion Adjuvants
- Liposomes and Archaeosomes
- Nanoparticles and Microparticles
- Others
By Route Of Administration
- Oral
- Subcutaneous
- Intramuscular
- Others
By Type Of Animal
- Livestock Animals
- Companion Animals
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- SEPPIC
- SPI Pharma, Inc.
- Bioveta AS
- Croda Internation PLC
- Merck & Co., Inc.
- MVP Laboratories
- OZ Biosciences
- InvivoGen Corporation.
- Evonik Industries AG
- Zoetis, Inc.

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VINCA ALKALOID COMPOUNDS MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Vinblastine
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Vincristine
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Vindesine
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: VINCA ALKALOID COMPOUNDS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Clinics
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Academic Research Institutes
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: VINCA ALKALOID COMPOUNDS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Product Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Vinca Alkaloid Compounds Market
6.2.5.1. Market Size and Forecast, By Product Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Vinca Alkaloid Compounds Market
6.2.6.1. Market Size and Forecast, By Product Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Vinca Alkaloid Compounds Market
6.2.7.1. Market Size and Forecast, By Product Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Product Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Vinca Alkaloid Compounds Market
6.3.5.1. Market Size and Forecast, By Product Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Vinca Alkaloid Compounds Market
6.3.6.1. Market Size and Forecast, By Product Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Vinca Alkaloid Compounds Market
6.3.7.1. Market Size and Forecast, By Product Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Vinca Alkaloid Compounds Market
6.3.8.1. Market Size and Forecast, By Product Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Vinca Alkaloid Compounds Market
6.3.9.1. Market Size and Forecast, By Product Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Vinca Alkaloid Compounds Market
6.3.10.1. Market Size and Forecast, By Product Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Product Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Vinca Alkaloid Compounds Market
6.4.5.1. Market Size and Forecast, By Product Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Vinca Alkaloid Compounds Market
6.4.6.1. Market Size and Forecast, By Product Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. Australia Vinca Alkaloid Compounds Market
6.4.7.1. Market Size and Forecast, By Product Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. India Vinca Alkaloid Compounds Market
6.4.8.1. Market Size and Forecast, By Product Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Vinca Alkaloid Compounds Market
6.4.9.1. Market Size and Forecast, By Product Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Vinca Alkaloid Compounds Market
6.4.10.1. Market Size and Forecast, By Product Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Product Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Vinca Alkaloid Compounds Market
6.5.5.1. Market Size and Forecast, By Product Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Vinca Alkaloid Compounds Market
6.5.6.1. Market Size and Forecast, By Product Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Vinca Alkaloid Compounds Market
6.5.7.1. Market Size and Forecast, By Product Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Vinca Alkaloid Compounds Market
6.5.8.1. Market Size and Forecast, By Product Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Accord Healthcare Limited
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Eli Lilly And Company.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Fresenius Kabi AG
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Medline Industries, LP.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Pfizer Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Pierre Fabre S.A
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Talon Pharmaceuticals
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Teva Pharmaceutical Industries Limited
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Viatris Inc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments

TABLE 1. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. VETERINARY VACCINE ADJUVANTS MARKET FOR ALUM AND CALCIUM SALTS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. VETERINARY VACCINE ADJUVANTS MARKET FOR OIL EMULSION ADJUVANTS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. VETERINARY VACCINE ADJUVANTS MARKET FOR LIPOSOMES AND ARCHAEOSOMES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. VETERINARY VACCINE ADJUVANTS MARKET FOR NANOPARTICLES AND MICROPARTICLES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. VETERINARY VACCINE ADJUVANTS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 8. VETERINARY VACCINE ADJUVANTS MARKET FOR ORAL, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. VETERINARY VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. VETERINARY VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. VETERINARY VACCINE ADJUVANTS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 13. VETERINARY VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. VETERINARY VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. VETERINARY VACCINE ADJUVANTS MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 18. NORTH AMERICA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 20. U.S. VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 21. U.S. VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 22. U.S. VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 23. CANADA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 24. CANADA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 25. CANADA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 28. MEXICO VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 31. EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 32. EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 33. GERMANY VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 34. GERMANY VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 35. GERMANY VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 36. FRANCE VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 37. FRANCE VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 38. FRANCE VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 39. UK VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 40. UK VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 41. UK VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 42. ITALY VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 43. ITALY VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 44. ITALY VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 45. SPAIN VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 46. SPAIN VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 47. SPAIN VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 49. REST OF EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 50. REST OF EUROPE VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 53. ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 54. ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 55. JAPAN VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 56. JAPAN VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 57. JAPAN VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 58. CHINA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 59. CHINA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 60. CHINA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 61. AUSTRALIA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 62. AUSTRALIA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 63. AUSTRALIA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 64. INDIA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 65. INDIA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 66. INDIA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 67. SOUTH KOREA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 68. SOUTH KOREA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 69. SOUTH KOREA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 71. REST OF ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 72. REST OF ASIA-PACIFIC VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 75. LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 76. LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 78. BRAZIL VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 79. BRAZIL VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 80. SAUDI ARABIA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 81. SAUDI ARABIA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 82. SAUDI ARABIA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 83. SOUTH AFRICA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 84. SOUTH AFRICA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 85. SOUTH AFRICA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 87. REST OF LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2024 - 2033 ($BILLION)
TABLE 88. REST OF LAMEA VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL, 2024 - 2033 ($BILLION)
TABLE 89. SEPPIC: KEY EXECUTIVES
TABLE 90. SEPPIC: COMPANY SNAPSHOT
TABLE 91. SEPPIC: OPERATING SEGMENTS
TABLE 92. SEPPIC: PRODUCT PORTFOLIO
TABLE 93. SEPPIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. SPI PHARMA, INC.: KEY EXECUTIVES
TABLE 95. SPI PHARMA, INC.: COMPANY SNAPSHOT
TABLE 96. SPI PHARMA, INC.: OPERATING SEGMENTS
TABLE 97. SPI PHARMA, INC.: PRODUCT PORTFOLIO
TABLE 98. SPI PHARMA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. BIOVETA AS: KEY EXECUTIVES
TABLE 100. BIOVETA AS: COMPANY SNAPSHOT
TABLE 101. BIOVETA AS: OPERATING SEGMENTS
TABLE 102. BIOVETA AS: PRODUCT PORTFOLIO
TABLE 103. BIOVETA AS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. CRODA INTERNATION PLC: KEY EXECUTIVES
TABLE 105. CRODA INTERNATION PLC: COMPANY SNAPSHOT
TABLE 106. CRODA INTERNATION PLC: OPERATING SEGMENTS
TABLE 107. CRODA INTERNATION PLC: PRODUCT PORTFOLIO
TABLE 108. CRODA INTERNATION PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 110. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 111. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 112. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 113. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. MVP LABORATORIES: KEY EXECUTIVES
TABLE 115. MVP LABORATORIES: COMPANY SNAPSHOT
TABLE 116. MVP LABORATORIES: OPERATING SEGMENTS
TABLE 117. MVP LABORATORIES: PRODUCT PORTFOLIO
TABLE 118. MVP LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 119. OZ BIOSCIENCES: KEY EXECUTIVES
TABLE 120. OZ BIOSCIENCES: COMPANY SNAPSHOT
TABLE 121. OZ BIOSCIENCES: OPERATING SEGMENTS
TABLE 122. OZ BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 123. OZ BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 124. INVIVOGEN CORPORATION.: KEY EXECUTIVES
TABLE 125. INVIVOGEN CORPORATION.: COMPANY SNAPSHOT
TABLE 126. INVIVOGEN CORPORATION.: OPERATING SEGMENTS
TABLE 127. INVIVOGEN CORPORATION.: PRODUCT PORTFOLIO
TABLE 128. INVIVOGEN CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129. EVONIK INDUSTRIES AG: KEY EXECUTIVES
TABLE 130. EVONIK INDUSTRIES AG: COMPANY SNAPSHOT
TABLE 131. EVONIK INDUSTRIES AG: OPERATING SEGMENTS
TABLE 132. EVONIK INDUSTRIES AG: PRODUCT PORTFOLIO
TABLE 133. EVONIK INDUSTRIES AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 134. ZOETIS, INC.: KEY EXECUTIVES
TABLE 135. ZOETIS, INC.: COMPANY SNAPSHOT
TABLE 136. ZOETIS, INC.: OPERATING SEGMENTS
TABLE 137. ZOETIS, INC.: PRODUCT PORTFOLIO
TABLE 138. ZOETIS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

FIGURE 1. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF VETERINARY VACCINE ADJUVANTS MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN VETERINARY VACCINE ADJUVANTS MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVETERINARY VACCINE ADJUVANTS MARKET
FIGURE 10. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET SEGMENTATION, BY TYPE
FIGURE 11. VETERINARY VACCINE ADJUVANTS MARKET FOR ALUM AND CALCIUM SALTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. VETERINARY VACCINE ADJUVANTS MARKET FOR OIL EMULSION ADJUVANTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. VETERINARY VACCINE ADJUVANTS MARKET FOR LIPOSOMES AND ARCHAEOSOMES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. VETERINARY VACCINE ADJUVANTS MARKET FOR NANOPARTICLES AND MICROPARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. VETERINARY VACCINE ADJUVANTS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
FIGURE 17. VETERINARY VACCINE ADJUVANTS MARKET FOR ORAL, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. VETERINARY VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. VETERINARY VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. VETERINARY VACCINE ADJUVANTS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. GLOBAL VETERINARY VACCINE ADJUVANTS MARKET SEGMENTATION, BY TYPE OF ANIMAL
FIGURE 22. VETERINARY VACCINE ADJUVANTS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. VETERINARY VACCINE ADJUVANTS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 28. COMPETITIVE DASHBOARD
FIGURE 29. COMPETITIVE HEATMAP: VETERINARY VACCINE ADJUVANTS MARKET
FIGURE 30. TOP PLAYER POSITIONING, 2023
FIGURE 31. SEPPIC: NET SALES, 2021-2023 ($BILLION)
FIGURE 32. SEPPIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 33. SEPPIC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 34. SPI PHARMA, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 35. SPI PHARMA, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 36. SPI PHARMA, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 37. BIOVETA AS: NET SALES, 2021-2023 ($BILLION)
FIGURE 38. BIOVETA AS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 39. BIOVETA AS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 40. CRODA INTERNATION PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 41. CRODA INTERNATION PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 42. CRODA INTERNATION PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 43. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 44. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 45. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 46. MVP LABORATORIES: NET SALES, 2021-2023 ($BILLION)
FIGURE 47. MVP LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 48. MVP LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 49. OZ BIOSCIENCES: NET SALES, 2021-2023 ($BILLION)
FIGURE 50. OZ BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 51. OZ BIOSCIENCES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 52. INVIVOGEN CORPORATION.: NET SALES, 2021-2023 ($BILLION)
FIGURE 53. INVIVOGEN CORPORATION.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 54. INVIVOGEN CORPORATION.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 55. EVONIK INDUSTRIES AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 56. EVONIK INDUSTRIES AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 57. EVONIK INDUSTRIES AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 58. ZOETIS, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 59. ZOETIS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 60. ZOETIS, INC.: REVENUE SHARE, BY REGION, 2023 (%)

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $2655.00 $2389.50
  • $5730.00 $5157.00
  • $7412.00 $6670.80
  • ADD TO BASKET
  • BUY NOW